Human UBXN4 (Erasin) knockout HeLa cell line
Human UBXN4 (Erasin) knockout HeLa cell line
Be the first to review this product! Submit a review
|
(0 Publication)
UBXN4 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 35 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
別名を表示する
Erasin, FLJ23318, KIAA0242, KIAA2042, UBX domain containing 1, UBX domain containing 2, UBX domain containing protein 2, UBXD 2, UBXDC 1
- Sanger seq
Unknown
Sanger Sequencing - Human UBXN4 (Erasin) knockout HeLa cell line (AB265897)
Homozygous : 35 bp deletion in exon 1.
製品の詳細
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
製品内容
出荷温度及び保存条件
遺伝子名
遺伝子編集のタイプ
遺伝子編集の方法
ノックアウト検証方法
接合型
出荷温度
短期保存温度
長期保存温度
取り扱い方法
初回取り扱いガイドライン
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
継代培養ガイドライン
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
培養培地
DMEM (High Glucose) + 10% FBS
凍結保存培地
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
補足情報
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The roles of Erasin extend beyond its chaperone activities. It is a component of a larger proteostasis network interacting with other cellular machineries to regulate degradation processes. Erasin helps in stabilizing misfolded proteins and prevents aggregation which could be harmful to the cell. Its presence in the endoplasmic reticulum signifies its function in protein quality control and stress response especially under conditions that challenge cellular homeostasis.
Pathways
Erasin actively participates in the unfolded protein response (UPR) and ER-associated degradation (ERAD) pathways. These pathways are important for eliminating defective proteins and maintaining cellular equilibrium. Erasin interacts closely with Bip and Calnexin both of which are key players in the ER stress response. By aiding these networks Erasin contributes to cellular health by ensuring that proteins achieve and maintain their correct structures.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female
ターゲットの情報
組合せ製品
Abcam product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com